MBX Biosciences, Inc.

The Company classifies its entire investment portfolio as available-for-sale as defined in ASC 320, Debt Securities, and views all investments as available for use in its current operations.

SEC original ↗MBX Biosciences, Inc. — 10-Q Quarterly report10-QAug 6, 2026

These shares were subject to the Company s option to repurchase and were not transferable until such time as they are fully vested.

SEC original ↗MBX Biosciences, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The 2024 Plan provides for the grant of incentive stock options, stock options, stock appreciation rights, restricted shares of common stock, RSUs, dividend equivalent rights and cash bonuses.

SEC original ↗MBX Biosciences, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The number of shares reserved under the 2024 Plan is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization.

SEC original ↗MBX Biosciences, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The number of shares reserved under the 2024 ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization.

SEC original ↗MBX Biosciences, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The 2026 Plan provides for the grant of nonqualified stock options, stock options, stock appreciation rights, restricted shares of common stock, RSUs, dividend equivalent rights and cash bonuses.

SEC original ↗MBX Biosciences, Inc. — 10-Q Quarterly report10-QAug 6, 2026

(Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the second quarter ended June 30, 2025, and highlighted recent corporate progress.

SEC original ↗MBX Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

About MBX Biosciences MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP platform, for the treatment of endocrine and metabolic disorders.

SEC original ↗MBX Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

( MBX or the Company ) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders.

SEC original ↗MBX Biosciences, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Related Party transactions In May 2026, the Company entered into a consulting agreement with Steven Hoerter, the executive chair of the Company's board of directors, to provide additional strategic advisory services to the Company.

SEC original ↗MBX Biosciences, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The CODM uses net loss to assess performance of the Company, ensuring that it is investing in the research and development of product candidates.

SEC original ↗MBX Biosciences, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect MBX Biosciences’ business, operating results, financial condition and stock value.

SEC original ↗MBX Biosciences, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Legal Proceedings 30 Item 1A.

SEC original ↗MBX Biosciences, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements.

SEC original ↗MBX Biosciences, Inc. — 10-Q Quarterly report10-QAug 6, 2026

You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results.

SEC original ↗MBX Biosciences, Inc. — 10-Q Quarterly report10-QAug 6, 2026

If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements.

SEC original ↗MBX Biosciences, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information.

SEC original ↗MBX Biosciences, Inc. — 10-Q Quarterly report10-QAug 6, 2026